Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience.
pancreatic cancer
sabr
sbrt
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
23 Sep 2020
23 Sep 2020
Historique:
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
31
10
2020
Statut:
epublish
Résumé
Introduction Despite treatment advances, the prognosis of locally advanced pancreatic cancer is poor. Treatment remains varied and includes systemic and radiotherapy (RT). Stereotactic body radiotherapy (SBRT), highly conformal high-dose RT per fraction, is an emerging treatment option. Materials and methods We performed a single-institution retrospective review of patients with pancreatic adenocarcinoma treated with SBRT from 2015-2017. The median dose was 27 Gy (range: 21-36 Gy) in three fractions. Endpoints included local progression (RECIST 1.1; Response Evaluation Criteria in Solid Tumors 1.1), distant metastasis, overall survival, and toxicity. Results Forty-one patients were treated, with a median follow-up of eight months. Patients who received SBRT had unresectable (49%), metastatic (17%), or borderline resectable (7%) disease, declined surgery (17%), medically inoperable (7%), or developed local recurrence following the Whipple procedure (2%). The six-month and one-year rates of local progression-free survival, distant metastasis-free survival, and overall survival were 62% and 55%, 44% and 32%, and 70% and 49%, respectively. Five patients (12%) experienced seven late gastrointestinal (GI) grade 3 events. Conclusion SBRT may be considered a treatment option to achieve local control of pancreatic cancer and is associated with a modest risk of severe late GI toxicities. Systemic therapies remain important, given the proportion of patients who develop distant metastases.
Identifiants
pubmed: 33123432
doi: 10.7759/cureus.10618
pmc: PMC7584314
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10618Informations de copyright
Copyright © 2020, Glicksman et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):918-25
pubmed: 25585785
Cancer. 2017 Sep 15;123(18):3486-3493
pubmed: 28493288
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22
pubmed: 23562768
Dig Liver Dis. 2018 Apr;50(4):396-400
pubmed: 29326012
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):641-8
pubmed: 24803041
J Surg Res. 2012 May 15;174(2):319-25
pubmed: 21937061
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e615-22
pubmed: 21658854
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):579-87
pubmed: 25680600
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):313-322
pubmed: 28068239
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42
pubmed: 20171803
Onco Targets Ther. 2015 Jun 12;8:1427-31
pubmed: 26109866
Expert Rev Anticancer Ther. 2013 Apr;13(4):481-7
pubmed: 23560842
Cancer. 2009 Feb 1;115(3):665-72
pubmed: 19117351
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):755-65
pubmed: 26972648
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
Expert Rev Anticancer Ther. 2016 May;16(5):523-30
pubmed: 26999329
Radiother Oncol. 2013 Jul;108(1):66-71
pubmed: 23726116
Technol Cancer Res Treat. 2017 Jun;16(3):295-301
pubmed: 27311310
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
Am J Clin Oncol. 2011 Feb;34(1):63-9
pubmed: 20308870